CO6270216A2 - Formulaciones galenicas de alisquireno - Google Patents
Formulaciones galenicas de alisquirenoInfo
- Publication number
- CO6270216A2 CO6270216A2 CO10045478A CO10045478A CO6270216A2 CO 6270216 A2 CO6270216 A2 CO 6270216A2 CO 10045478 A CO10045478 A CO 10045478A CO 10045478 A CO10045478 A CO 10045478A CO 6270216 A2 CO6270216 A2 CO 6270216A2
- Authority
- CO
- Colombia
- Prior art keywords
- dosage form
- oral dosage
- present
- solid oral
- percent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 abstract 9
- 239000007787 solid Substances 0.000 abstract 7
- 239000004480 active ingredient Substances 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a una forma de dosificacion oral solida compactada con rodillo que comprende una cantidad terapéuticamente efectiva de alisquireno, o una sal farmacéuticamente aceptable del mismo, en donde el ingrediente activo esta presente en una cantidad mayor del 38 por ciento en peso, con base en el peso total de la forma de dosificacion oral, asi como a un proceso para preparar la forma de dosificacion oral solida. 1.- Una forma de dosificacion oral solida que comprende una cantidad terapéuticamente efectiva de alisquireno, o una sal farmacéuticamente aceptable del mismo, en donde el ingrediente activo esta presente en una cantidad mayor del 38 por ciento en peso, con base en el peso total de la forma de dosificacion oral. 2.- Una forma de dosificacion oral solida de acuerdo con la reivindicacion 1, en donde el ingrediente activo esta presente en una cantidad mayor del 40 por ciento en peso. 3.- Una forma de dosificacion oral solida de acuerdo con la Reivindicacion 1 o 2, en donde el ingrediente activo esta presente en una cantidad en un intervalo del 41 al 80 por ciento, tal como del 41 al 60 por ciento en peso. 4.- Una forma de dosificacion oral solida de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el ingrediente activo consiste completamente en alisquireno, o una sal farmacéuticamente aceptable del mismo, y esta presente en una cantidad en el intervalo de aproximadamente 75 a aproximadamente 300 miligramos de la base libre por forma de dosificacion unitaria. 5.- Una forma de dosificacion oral solida de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el alisquireno esta en la forma de un hemi-fumarato del mismo, y esta presente en una cantidad de aproximadamente 84, aproximadamente 166, o aproximadamente 332 miligramos por forma de dosificacion unitaria.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97589407P | 2007-09-28 | 2007-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270216A2 true CO6270216A2 (es) | 2011-04-20 |
Family
ID=40377181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10045478A CO6270216A2 (es) | 2007-09-28 | 2010-04-19 | Formulaciones galenicas de alisquireno |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20110033533A1 (es) |
| EP (2) | EP2205232A2 (es) |
| JP (1) | JP5378384B2 (es) |
| KR (1) | KR20100076996A (es) |
| CN (1) | CN101808630A (es) |
| AR (1) | AR068539A1 (es) |
| AU (1) | AU2008303504C1 (es) |
| BR (1) | BRPI0817586A2 (es) |
| CA (1) | CA2697229A1 (es) |
| CL (1) | CL2008002828A1 (es) |
| CO (1) | CO6270216A2 (es) |
| GT (1) | GT201000064A (es) |
| MA (1) | MA31768B1 (es) |
| MX (1) | MX2010003260A (es) |
| MY (1) | MY148266A (es) |
| NZ (1) | NZ584005A (es) |
| PE (1) | PE20091203A1 (es) |
| RU (1) | RU2483718C2 (es) |
| TN (1) | TN2010000120A1 (es) |
| TW (1) | TWI436760B (es) |
| WO (1) | WO2009040373A2 (es) |
| ZA (1) | ZA201001144B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201008902A (en) * | 2008-05-23 | 2010-03-01 | Teva Pharma | Aliskiren monofumarate and processes for preparation thereof |
| WO2011116115A1 (en) | 2010-03-16 | 2011-09-22 | Novartis Ag | Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing |
| TR201002256A1 (tr) | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
| EP2382969A1 (en) | 2010-04-30 | 2011-11-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multicoated Aliskiren formulations |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| WO2002043807A2 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
| RU2183116C1 (ru) * | 2001-07-10 | 2002-06-10 | Жаров Олег Владимирович | Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием |
| US20040266743A1 (en) * | 2003-05-09 | 2004-12-30 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a renin inhibitor |
| PE20142101A1 (es) | 2004-03-17 | 2014-12-27 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
| US20050220865A1 (en) * | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| KR20080000624A (ko) * | 2005-04-27 | 2008-01-02 | 노파르티스 아게 | 아테롬성동맥경화증의 치료 방법 |
| KR20080066776A (ko) * | 2005-11-08 | 2008-07-16 | 노파르티스 아게 | 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물 |
| TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
| GB0605688D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
| US20100130616A1 (en) * | 2006-11-09 | 2010-05-27 | Novartis Ag | Salt of aliskiren with orotic acid |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| AU2008309058B2 (en) * | 2007-09-28 | 2012-08-09 | Novartis Ag | Galenical formulations of Aliskiren and Valsartan |
-
2008
- 2008-09-24 WO PCT/EP2008/062769 patent/WO2009040373A2/en active Application Filing
- 2008-09-24 JP JP2010526278A patent/JP5378384B2/ja not_active Expired - Fee Related
- 2008-09-24 CN CN200880108854A patent/CN101808630A/zh active Pending
- 2008-09-24 AR ARP080104136A patent/AR068539A1/es unknown
- 2008-09-24 BR BRPI0817586 patent/BRPI0817586A2/pt not_active IP Right Cessation
- 2008-09-24 PE PE2008001663A patent/PE20091203A1/es not_active Application Discontinuation
- 2008-09-24 TW TW097136655A patent/TWI436760B/zh not_active IP Right Cessation
- 2008-09-24 RU RU2010116530/15A patent/RU2483718C2/ru not_active IP Right Cessation
- 2008-09-24 MX MX2010003260A patent/MX2010003260A/es active IP Right Grant
- 2008-09-24 EP EP08804674A patent/EP2205232A2/en not_active Withdrawn
- 2008-09-24 EP EP12188621A patent/EP2548553A1/en not_active Withdrawn
- 2008-09-24 KR KR1020107009195A patent/KR20100076996A/ko not_active Application Discontinuation
- 2008-09-24 US US12/679,088 patent/US20110033533A1/en not_active Abandoned
- 2008-09-24 MY MYPI2010000722A patent/MY148266A/en unknown
- 2008-09-24 CL CL2008002828A patent/CL2008002828A1/es unknown
- 2008-09-24 CA CA2697229A patent/CA2697229A1/en not_active Abandoned
- 2008-09-24 AU AU2008303504A patent/AU2008303504C1/en not_active Ceased
- 2008-09-24 NZ NZ584005A patent/NZ584005A/xx not_active IP Right Cessation
-
2010
- 2010-02-17 ZA ZA2010/01144A patent/ZA201001144B/en unknown
- 2010-03-17 GT GT201000064A patent/GT201000064A/es unknown
- 2010-03-19 TN TNP2010000120A patent/TN2010000120A1/fr unknown
- 2010-04-08 MA MA32758A patent/MA31768B1/fr unknown
- 2010-04-19 CO CO10045478A patent/CO6270216A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101808630A (zh) | 2010-08-18 |
| AU2008303504A1 (en) | 2009-04-02 |
| WO2009040373A2 (en) | 2009-04-02 |
| RU2483718C2 (ru) | 2013-06-10 |
| EP2548553A1 (en) | 2013-01-23 |
| NZ584005A (en) | 2012-08-31 |
| US20110033533A1 (en) | 2011-02-10 |
| MX2010003260A (es) | 2010-04-29 |
| TN2010000120A1 (en) | 2011-09-26 |
| WO2009040373A3 (en) | 2009-08-20 |
| AR068539A1 (es) | 2009-11-18 |
| AU2008303504B2 (en) | 2012-03-22 |
| TWI436760B (zh) | 2014-05-11 |
| MA31768B1 (fr) | 2010-10-01 |
| JP2010540489A (ja) | 2010-12-24 |
| BRPI0817586A2 (pt) | 2015-03-31 |
| PE20091203A1 (es) | 2009-09-11 |
| TW200922546A (en) | 2009-06-01 |
| JP5378384B2 (ja) | 2013-12-25 |
| GT201000064A (es) | 2012-03-30 |
| CL2008002828A1 (es) | 2009-05-15 |
| EP2205232A2 (en) | 2010-07-14 |
| AU2008303504C1 (en) | 2013-05-16 |
| KR20100076996A (ko) | 2010-07-06 |
| RU2010116530A (ru) | 2011-11-10 |
| CA2697229A1 (en) | 2009-04-02 |
| ZA201001144B (en) | 2011-12-28 |
| MY148266A (en) | 2013-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| AR070731A1 (es) | Composicion farmaceutica para farmacos poco solubles | |
| PE20200175A1 (es) | Formas de dosificacion de ruxolitinib de liberacion sostenida | |
| MX2010005632A (es) | Analogos de aminoglucosidos antibacterianos. | |
| ECSP12011958A (es) | Composiciones farmacéuticas que comprenden ligandos de receptores sigma | |
| PE20120476A1 (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| DOP2012000011A (es) | Formulacion farmaceutica | |
| UA110013C2 (uk) | Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів | |
| CL2009001016A1 (es) | Preparacion farmaceutica solida con liberacion retardada que comprende: a) un ingrediente farmaceuticamente activo, b) 15 a 40% en peso de una mezcla de polivinilpirrolidona y/o un derivado de polivinilpirrolidona y c) al menos un diluyente. | |
| MX2010006284A (es) | Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal. | |
| WO2008023016A3 (en) | Galenic formulations of aliskiren | |
| CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
| CO6640318A2 (es) | Formas de dosificación oral de bendamustina | |
| PE20150773A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilefrina | |
| AR062393A1 (es) | Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor | |
| CO6270216A2 (es) | Formulaciones galenicas de alisquireno | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| CU20140028A7 (es) | Compuesto de benzotiazolona | |
| AR062239A1 (es) | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal | |
| ECSP11010998A (es) | Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundida | |
| WO2008065144A3 (en) | Galenic formulations of organic compounds | |
| AR077451A1 (es) | Utilizacion de benzidamina en el tratamiento de enfermedades dependientes de p40 | |
| ATE525064T1 (de) | Pharmazeutische zusammensetzung mit desloratadin | |
| TR200802061A2 (tr) | Yüksek oranda aktif madde içeren farmasötlk formülasyon. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FC | Application refused |